Published online before print December 12, 2008, doi: 10.1161/CIRCRESAHA.108.190397
© 2009 American Heart Association, Inc.
Integrative Physiology |
Estrogen Attenuates Left Ventricular and Cardiomyocyte Hypertrophy by an Estrogen Receptor–Dependent Pathway That Increases Calcineurin Degradation
From the Molecular Cardiology Research Institute (C.D., S.E., C.B., M.J.A., A.D.W., M.H.-P., F.W., A.A., R.H.K., R.D.P.), Tufts Medical Center, Boston, Mass; and Molecular Cardiovascular Biology Division (J.D.M.), Department of Pediatrics, Cincinnati Children’s Medical Center, Ohio.
Correspondence to Richard D. Patten, MD, Assistant Professor of Medicine, Department of Medicine, Tufts–New England Medical Center, 750 Washington St, Boston, MA 02111. E-mail rpatten{at}tuftsmedicalcenter.org
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Left ventricular (LV) hypertrophy commonly develops in response to chronic hypertension and is a significant risk factor for heart failure and death. The serine-threonine phosphatase calcineurin (Cn)A plays a critical role in the development of pathological hypertrophy. Previous experimental studies in murine models show that estrogen limits pressure overload–induced hypertrophy; our purpose was to explore further the mechanisms underlying this estrogen effect. Wild-type, ovariectomized female mice were treated with placebo or 17β-estradiol (E2), followed by transverse aortic constriction (TAC), to induce pressure overload. At 2 weeks, mice underwent physiological evaluation, immediate tissue harvest, or dispersion of cardiomyocytes. E2 replacement limited TAC-induced LV and cardiomyocyte hypertrophy while attenuating deterioration in LV systolic function and contractility. These E2 effects were associated with reduced abundance of CnA. The primary downstream targets of CnA are the nuclear factor of activated T-cell (NFAT) family of transcription factors. In transgenic mice expressing a NFAT-activated promoter/luciferase reporter gene, E2 limited TAC-induced activation of NFAT. Moreover, the inhibitory effects of E2 on LV hypertrophy were absent in CnA knockout mice, supporting the notion that CnA is an important target of E2-mediated inhibition. In cultured rat cardiac myocytes, E2 inhibited agonist-induced hypertrophy while also decreasing CnA abundance and NFAT activation. Agonist stimulation also reduced CnA ubiquitination and degradation that was prevented by E2; all in vitro effects of estrogen were reversed by an estrogen receptor (ER) antagonist. These data support that E2 reduces pressure overload induced hypertrophy by an ER-dependent mechanism that increases CnA degradation, unveiling a novel mechanism by which E2 and ERs regulate pathological LV and cardiomyocyte growth.
Key Words: estrogen • left ventricular remodeling • pressure overload • myocyte hypertrophy • calcineurin proteasome • ubiquitin
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Chronic pressure overload such as hypertension commonly leads to left ventricular (LV) hypertrophy, which is a major risk factor for the development of heart failure and death.1,2 LV hypertrophy is reflective of changes in the extracellular matrix and cardiomyocyte hypertrophy, both of which result from activation of signaling pathways and a reprogramming of gene expression.3,4 The calcium/calmodulin-dependent serine–threonine phosphatase calcineurin plays an important role in pathological cardiomyocyte hypertrophy.5,6 The primary targets of calcineurin are the nuclear factor of activated T cell (NFAT) family of transcription factors. NFAT intracellular localization and function is regulated by its phosphorylation state. Under basal conditions, NFAT proteins are hyperphosphorylated and localize to the cytoplasm.7 On hypertrophic stimulation, specific N-terminal serine residues in NFAT proteins are dephosphorylated by the catalytic "A" subunit of calcineurin (CnA), allowing nuclear localization of NFAT that, in cooperation with other transcription factors, activates the hypertrophic gene program.
Clinical and experimental studies have established that sex influences the patterns of LV hypertrophy.8 For example, in response to pressure overload, such as hypertension or aortic stenosis, human male hearts exhibit LV dilatation or eccentric hypertrophy, whereas female hearts tend to maintain normal chamber size but develop increased wall thickness, consistent more with concentric hypertrophy.9 Although sex differences provide no direct evidence that sex hormones influence the patterns of hypertrophy, we and others have demonstrated that physiological replacement of 17β-estradiol (E2), the main circulating form of estrogen in premenopausal women, to ovariectomized female mice limits pressure overload–induced LV hypertrophy.10,11 In this study, we characterize further the molecular mechanisms that contribute to the effects of estrogen on LV hypertrophy in response to pressure overload, focusing on components of the calcineurin signaling pathway.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Materials
All chemical agents were obtained from Sigma. Polymerase chain reaction (PCR) reagents were obtained from Invitrogen. For details regarding antibodies and plasmid and adenoviral vectors, see the expanded Materials and Methods section in the online data supplement, available at http://circres.ahajournals.org.
Animals
Eight- to 10-week-old female C57BL/6 mice were cared for as described.10,12 This protocol was approved by the Institutional Animal Care and Use Committee at the Tufts–New England Medical Center. Transgenic mice that ubiquitously express a NFAT-activated promoter/luciferase reporter gene and mice with a disrupted CnAβ gene (CnAβ knockout [KO] mice) have been previously reported.13,14
Surgical Procedures
Procedures were performed under general anesthesia using 2.0% to 2.5% isoflurane. Ovariectomy, subcutaneous pellet placement, and transverse aortic constriction (TAC) were performed as described previously.10,12 Estrogen or placebo was administered via 60-day release pellets placed subcutaneously (0.25 mg/60 day release pellet; Innovative Research of America, Sarasota, Fla).
Echocardiography
Transthoracic echocardiography was performed under light sedation with 1.0% isoflurane as described.12,15
Closed Chest Hemodynamic Evaluation
Closed chest hemodynamics were measured as described.10,15 Pressure–volume (PV) loop analyses were performed from the right carotid artery using a fully calibrated, 1.0Fr PV conductance catheter (PVR-1045; Millar Instruments, Houston, Tex). TAC pressure gradients were quantified by also cannulating the left carotid with a 1.0Fr microtip pressure transducer (model SPR-1000; Millar Instruments) and measuring aortic pressure beyond the stricture. Hemodynamics were recorded and analyzed with IOX version 1.8.11 software (EMKA Instruments, Falls Church, Va). Preload recruitable stroke work was derived from the PV loops recorded during inferior vena cava occlusion because this measure is derived independent of loading conditions, chamber size, or calibration.16 All hemodynamic derivations were based on previous work by Georgakopoulos et al17 Parallel conductance corrections were performed in duplicate for each animal by injecting 10 µL of 15% NaCl solution into the external jugular vein.
Dispersion of Adult Mouse Myocytes for Morphometric Analysis
Myocytes from adult mice were enzymatically dispersed as described.18 The final buffer was supplemented with an excess of KCl (30 mmol/L) to suppress contraction. Cells were cover slipped and imaged at 100x magnification; cell size measurements were performed in a blinded fashion.
Primary Neonatal Rat Ventricular Myocyte Culture and Transfection
Neonatal rat ventricular myocytes (NRVMs) were cultured as described.19 For plasmid–DNA transfection, the calcium phosphate method was used as described.20 For replication deficient adenoviruses, a multiplicity of infection of 5 was added on plating and allowed to incubate overnight.
Adult Rat Ventricular Myocyte Cultures
Adult rat ventricular myocytes (ARVMs) were isolated from male rats weighing 200 to 250 g (approximately 8 to 10 weeks old) as described.21 Cells were allowed to settle by gravity through 6% BSA in media (low glucose DMEM supplemented with 0.1% BSA, 5 mmol/L taurine, 5 mmol/L carnitine, and 2 mmol/L creatine [ACCT media]), and the final pellet was resuspended in ACCT media and plated on to laminin-coated plates.
Semiquantitative Real-Time RT-PCR
From frozen LV segments or cells in culture, total cellular RNA was isolated as described.15 cDNA was made using the Quantifect cDNA synthesis kit (Qiagen) according to the instructions of the manufacturer. Real-time PCR was performed on all samples in triplicate using SYBR Green (Applied Biosystems).
Immunoprecipitation
Immunoprecipitations (IPs) were performed in lysis buffer supplemented with 10 mmol/L N-ethylmaleimide to inhibit ubiquitin-degrading enzymes. Five micrograms of anti-CnA (BD Biosciences; Clone G182-1847) or anti-myc antibody (mouse monoclonal; Tufts University Core Facility) was added to lysates (300 µg) and rocked overnight at 4°C followed by rocking with Protein A– or G–coated sepharose beads (GE-Amersham) for 1 hour at 4°C. Negative controls consisted of nonimmune, mouse IgG. Beads were pelleted by centrifugation, washed 4x in 750 µL of ice-cold PBS, and suspended in 2x sample buffer. Pellets were analyzed by SDS-PAGE.
Luciferase Assays
Twenty four hours after stimulation, cells were lysed and assayed for luciferase (Luciferase Assay System; Promega) and β-galactosidase activity (Applied Biosystems) to normalize for transfection efficiency. All assays were performed with a 96-well plate luminometer (Ascent, ThermoElectron, Waltham, Mass).
Statistical Analysis
All data are shown as means±SEM. When comparing multiple groups, 1-way ANOVA was performed and when significant (P<0.05), comparisons between each group were conducted using the Student–Newman–Keuls test, and a probability value of <0.05 was considered statistically significant. No significant differences between placebo-sham and E2-sham groups were observed in any of the variables studied. These data were therefore pooled.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The experimental design for most in vivo studies is shown in Figure I in the online data supplement. In studies using wild-type mice, there were 4 groups: placebo-sham, E2-sham, placebo-TAC, and E2-TAC. A total of 88 female C57/BL6 mice were used: 26 animals were divided equally into the placebo-sham and E2-sham groups; 62 mice underwent TAC; 29 were randomized to placebo; and 33 to E2. One death occurred in the shams (E2), 3 deaths in the placebo-TAC, and 3 deaths in the E2-TAC groups, giving a total of 81 survivors.
E2 replacement increased uterine weight (79.8±7.8 mg) compared to placebo-treated mice (sham and TAC groups; 9.7±1.1 mg; P<0.001 versus E2-treated). Plasma estradiol levels were not measured but the protocol used in these studies is identical to that from prior studies in which E2 levels were in the high physiological range.10,12
TAC significantly increased LV mass in the placebo group that was limited by E2 replacement (see Table). TAC led to increases in LV end diastolic diameter and end systolic diameter, and decreased fractional shortening in placebo-treated mice; E2 replacement normalized these parameters. A subgroup of mice underwent echocardiography while awake (n=27), demonstrating similar findings (supplemental Figure II). TAC produced similar LV systolic pressures and gradients in the E2- and placebo-treated mice, both being statistically greater than shams. In the placebo group, TAC significantly increased LV end diastolic pressure and decreased maximal LV dP/dt, both of which were improved by E2 replacement.
|
Data from PV loop analyses (n=25) are shown in the Table and Figure 1A. TAC led to reductions in stroke volume and cardiac output, both of which were improved by E2 replacement. TAC markedly decreased 2 measures of contractility derived from PV loop analyses: the slope of the end systolic PV relationship and preload recruitable stroke work. Both of these measures were normalized by E2 replacement. As displayed in Figure 1A, TAC caused significant LV dilatation in the placebo group, as indicated by a rightward shift in the steady state PV loop. E2 replacement attenuated TAC-induced LV dilatation and partially restored LV ejection fraction.
|
P<0.05 vs placebo-TAC. B, Myocyte morphometry results. Top, Representative images of dispersed myocytes from a sham, placebo-TAC, and E2-TAC heart. Bottom left, Myocyte 2D area. Middle, Myocyte length. Right, Myocyte width. TAC significantly increased myocyte area, length, and width in the placebo-treated mice. E2 replacement limited myocyte enlargement by attenuating the increase in myocyte length with no effect on myocyte width (n=9 shams; n=6 placebo-TAC mice; n=8 E2-TAC mice). Equivalent TAC gradients were confirmed by pulse wave Doppler measurements during echocardiography. *P<0.05 vs shams, Morphometric measurements were performed on freshly dispersed cardiomyocytes obtained from 23 mice (Figure 1B). TAC significantly increased myocyte area, length, and width in placebo-treated mice compared to shams; E2 replacement attenuated the increases in myocyte area and length, whereas no significant effect was observed on myocyte width post-TAC. These data support that E2 replacement limits pressure overload–induced hypertrophy by preventing myocyte elongation, LV chamber dilation, and dysfunction, thereby promoting a more concentric pattern of hypertrophy. TAC also increased atrial natriuretic peptide (ANP) and β-myosin heavy chain (β-MHC) gene expression, both of which were limited by E2 replacement (supplemental Figure III, A).
We next examined the effects of E2 on TAC-induced changes in the cardiac expression of CnA. Of the 3 known isoforms, CnAβ has been implicated in pathological cardiac hypertrophy.14 Neither TAC nor E2 treatment significantly altered the abundance of CnAβ mRNA (supplemental Figure III, B). However, CnA protein abundance rose significantly in placebo-treated mice following TAC (Figure 2A), and this was reversed by E2 replacement. We measured the expression of a splice variant of modulatory calcineurin interacting protein 1 (MCIP1).4 that harbors multiple NFAT-binding sites in the intron region upstream to exon 4. MCIP1.4 expression is, therefore, a reflection of calcineurin–NFAT activation.22 MCIP1.4 mRNA was increased in placebo-TAC hearts compared to shams and this was attenuated by E2 replacement (Figure 2A). Taken together, these data support that E2 attenuates the rise CnA protein expression and activity following TAC.
|
To examine further the effect of E2 replacement on calcineurin–NFAT activation, we used transgenic mice (n=18) that express a NFAT-activated promoter/luciferase reporter transgene, applying the same paradigm (supplemental Figure I). Luciferase assays performed on myocardial lysates demonstrated significantly increased luciferase activity in the placebo-TAC group compared to shams that was attenuated by E2 replacement (Figure 2B), supporting further that E2 limits TAC-induced calcineurin–NFAT activation. We next examined the effects of E2 replacement on TAC-induced hypertrophy in female homozygous CnAβ KO mice (n=20) using their wild-type littermates as controls (n=27). The same experimental paradigm was followed (supplemental Figure I). However, because CnAβ mice have been previously shown to have a marked blunting of the hypertrophic response 14 days following abdominal aortic banding,14 mice were analyzed 28 days following TAC to allow for the development of a greater degree of hypertrophy. E2 replacement attenuated LV hypertrophy in wild types following TAC (Figure 2C). The percentage increase in LV mass compared to shams in placebo-treated CnAβ KO mice was considerably less than corresponding wild types (28.7±7.3% versus 70.0±4.6%; P<0.01); E2 had no effect on LV hypertrophy in CnAβ KO mice, indicating that the attenuation of pressure overload–induced hypertrophy by E2 requires CnAβ, supporting further that calcineurin is a critical target of E2-mediated inhibition.
To explore the mechanisms of E2 effects on cardiomyocyte hypertrophy and calcineurin signaling, we used primary cultures of NRVMs stimulated with the 
1 adrenergic receptor agonist phenylephrine (PE). Physiological concentrations of E2 (10 nmol/L) inhibited PE-induced increase in cardiomyocyte cell area (Figure 3A) and ANP expression (Figure 3B), both of which were reversed by the estrogen receptor (ER) antagonist, ICI 182,780 (ICI), supporting an ER-dependent mechanism. Similar findings were observed in ARVMs (supplemental Figure IV, A and C).
|
E2 also attenuated the PE-induced increase in CnA protein abundance that was reversed by ICI (Figure 4A), supporting an ER-dependent mechanism. Moreover, E2 limited the PE-induced increase in CnAβ protein levels, whereas no effect on CnAβ mRNA was observed at 6 and 24 hours following PE stimulation (supplemental Figure IV, B). In NRVMs transfected with an NFAT-activated promoter/luciferase-reporter plasmid, E2 attenuated the PE-induced increase in NFAT activation (Figure 4A). To ascertain whether the E2-effects on CnA were required for inhibition of cell growth, NRVMs were infected with an adenovirus encoding a constitutively active mutant of CnA (caCnA) or green fluorescent protein (GFP) as a control. E2 had no effect on the increase in cell area in NRVMs expressing caCnA, although E2 limited the PE-induced increase in cell size in Adv-GFP–infected NRVMs (Figure 4B). E2 also had no effect on NFAT activation in the caCnA infected cells but attenuated NFAT activation in GFP-expressing cells stimulated with PE. NRVMs were next pretreated with E2, the calcineurin inhibitor, cyclosporine (500 ng/mL) or their combination (Figure 4C), followed by stimulation with PE. Importantly, E2 exhibited no additional inhibition of cell growth when combined with cyclosporine. Taken together, these findings support that calcineurin is an important target of E2-ER–mediated inhibition during agonist-induced hypertrophy.
|
Because E2 limits the PE-induced increase in CnA protein abundance without significantly altering mRNA levels, we explored whether E2 influences CnA degradation. NRVMs were pretreated with the protein synthesis inhibitor cycloheximide (40 µg/mL) before stimulation with PE. As shown in Figure 4D, the half-life of CnA in control cells was 15.1 hours, and this was significantly prolonged by PE, supporting the notion that the PE-induced increase in CnA abundance is attributable, in part, to reduced CnA degradation. In the presence of cycloheximide, E2 attenuated the PE-induced stabilization of CnA that was reversed by ICI, supporting the notion that E2 limits the increase in CnA abundance by increasing CnA degradation through an ER-dependent mechanism.
Calcineurin degradation occurs via the 26S proteasome.23 We therefore pretreated cardiomyocytes with the 26S proteasome inhibitor, lactacystin (10 µmol/L). Lactacystin increased CnA levels (Figure 5A) compared to untreated cells, and this was not altered further by PE treatment and/or E2, supporting the notion that a functional 26S proteasome is important for the regulation of CnA expression both by PE and E2. Lactacystin also abolished the E2-mediated attenuation of PE-induced increase in cardiomyocyte cell size (Figure 5B). A critical component of protein degradation is the addition of polyubiquitin chains to specific lysine residues on targeted proteins. We thus examined whether E2 pretreatment influenced CnA ubiquitination during agonist-induced hypertrophy. Figure 5C demonstrates that CnA ubiquitination was decreased by PE stimulation, whereas E2 pretreatment increased CnA ubiquitination following PE stimulation. Taken together, these data support that E2 attenuates the hypertrophic agonist-induced increase in CnA protein abundance by an ER-dependent mechanism that increases CnA ubiquitination and proteasomal degradation.
|
P<0.05 vs lactacystin alone. C, PE diminishes CnA ubiquitination, which is restored by E2 pretreatment. NRVMs were pretreated overnight with E2 on serum deprivation and stimulated with PE. Cells were harvested 4 hours later, and IPs of CnA were performed and analyzed by SDS-PAGE. Negative controls consisted of nonimmune mouse IgG precipitated in exactly the same way as CnA. PE stimulation reduced CnA ubiquitination, which was restored by E2 pretreatment. The bar graph represents data from 5 separate experiments. *P<0.01 vs control, CnA degradation has been shown previously to depend on the specific E3 ubiquitin ligase atrogin1, which associates with calcineurin and catalyzes CnA ubiquitination.23 We therefore quantified the mRNA expression of atrogin1 and -2 other E3 ubiquitin ligases, mouse double minute 2 (MDM2) and muscle-specific ring finger protein 1 (MuRF1), using myocardial RNA obtained from our TAC study in wild-type mice (n=25 samples; Figure 6). TAC induced a significant decline in the expression of atrogin1, MDM2, and MuRF1 in placebo-treated mice. E2 replacement had no effect on the TAC-induced decrease in atrogin1 expression but restored the expression of both MDM2 and MuRF1 to levels similar to shams.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Summary of Present Findings
We investigated the molecular mechanisms underlying the inhibitory effects of estrogen replacement on pressure overload–induced LV hypertrophy in the mouse TAC model. Consistent with prior studies, including our own,10,11 estrogen replacement limits pressure overload–induced LV hypertrophy. Perhaps more importantly, estrogen favorably influenced the remodeling phenotype by reversing TAC-induced LV dilatation and systolic dysfunction, while also preventing the decline in contractility following TAC. One striking and novel finding from our study was that E2 replacement limits TAC-induced myocyte hypertrophy largely by inhibiting myocyte elongation without affecting myocyte width. Taken together, our in vivo data support that E2 replacement promotes a more concentric pattern of hypertrophy and preserves LV systolic function and contractility.
The favorable effects of E2 replacement on LV and myocyte hypertrophy were accompanied by a reduction in the TAC-induced increase in calcineurin protein abundance and activity. Furthermore, absence of an effect of E2 in CnAβ KO mice following TAC further strengthens our hypothesis that calcineurin is likely a critical target of estrogen-mediated inhibition.
Our in vitro experiments provide further insight into a novel mechanism by which E2 influences hypertrophy and calcineurin signaling. First, the inhibitory effects of E2 on hypertrophic agonist-induced increase in calcineurin protein expression and cardiomyocyte hypertrophy are reversed by an ER antagonist supporting an ER-dependent pathway. Additionally, we observed no additive effect of E2 when combined with pharmacological inhibition of calcineurin. The absence of E2 effects in NRVMs and ARVMs overexpressing a constitutively active mutant of CnA support further that the calcineurin pathway is an important E2-regulated target. We also observed the novel finding that estrogen limits the hypertrophic stimulus-induced increase in CnA abundance by increasing its ubiquitination and proteasomal degradation, thereby limiting CnA-dependent activation of the hypertrophic gene program. Taken together, these data support the overall conclusion that estrogen replacement limits LV and cardiomyocyte hypertrophy, in part, by an ER-dependent pathway that increases proteasome-mediated degradation of calcineurin.
Prior Studies
The mechanisms by which estrogen and its receptors influence pathological cardiomyocyte growth are complex and multifaceted. van Eickels et al demonstrated in vivo that E2-mediated reduction in TAC-induced hypertrophy in ovariectomized female mice was associated with an unexpected rise in ANP expression.11 In our studies, the effects of E2 on ANP mRNA expression mirrored its effects on cardiomyocyte growth. Differences between our findings and that of van Eickels may be related to the time period after TAC (2 versus 4 weeks) or that we measured mRNA, whereas van Eickels quantified ANP protein by Western blotting.
Pedram et al24 demonstrated that E2 increased the expression of the calcineurin regulatory protein MCIP1 and that small interfering RNA knockdown of MCIP1 abolished the inhibitory effects of E2 on agonist-induced hypertrophy. Our results appear, at face value, to differ from these in several respects, although the study by Pedram et al used cultured neonatal cardiac myocytes, whereas our results on MICP1 expression were obtained from in vivo myocardial samples. Moreover, we quantified the MCIP1 isoform whose expression is driven by NFAT activation (MCIP1.4). MCIP1.4 mRNA levels corroborated with LV mass and calcineurin protein expression data, increasing in the placebo-TAC group and being attenuated by E2 replacement. We also quantified the expression of exon 7, common to all MCIP1 splice variants, and observed no significant differences following TAC. Studies using overexpression strategies in vitro25,26 and cardiac-specific, transgenic approaches in vivo27 have shown that MCIP1 inhibits calcineurin activation and pathological hypertrophy. However, MCIP1 KO mice surprisingly developed paradoxically less TAC-induced hypertrophy and calcineurin activation,28 suggesting that, at physiological expression levels, MCIPs may facilitate, rather than inhibit, calcineurin activation and LV hypertrophy. It is apparent that regulation of calcineurin activation and cardiomyocyte growth by MCIPs is complex, and the manner in which these calcineurin regulatory proteins participate in the E2 effects on hypertrophy deserves further investigation.
We demonstrate here that E2 limits the hypertrophic stimulus–induced rise in CnA protein expression by increasing its degradation, an effect that is ER-dependent. Calcineurin was shown by Li et al to associate with the E3 ubiquitin ligase, atrogin1.23 Overexpression of atrogin1 inhibited agonist-induced NRVM hypertrophy in vitro and pressure overload–induced LV hypertrophy in vivo, while concomitantly limiting the rise in calcineurin protein abundance and activity. We observed in vivo that TAC decreases the expression of atrogin1 with no effect of E2 replacement, suggesting that the E2 effects on calcineurin degradation are not the result of an effect on atrogin1 transcription. Interestingly, E2 replacement normalized the TAC-induced decrease in the expression of two other E3 ubiquitin ligases that may have potentially important effects on myocyte hypertrophy. Further work will be required to elucidate the mechanisms by which E2 and ERs increase calcineurin degradation and the contribution of MDM2 and MuRF1 to the estrogen-mediated attenuation of pressure overload hypertrophy. Based on our data, we propose a model shown in Figure 7.
|
The present findings may have important clinical implications because the development of cardiac-specific, selective estrogen receptor modulators that produce favorable estrogenic effects on the myocardium without inducing unfavorable effects in other tissues (eg, activation of coagulation factors) may hold therapeutic promise for reducing left ventricular hypertrophy.
In summary, we demonstrate that estrogen replacement limits pressure overload–induced LV dilation and cardiomyocyte hypertrophy in vivo and in vitro, promoting a more concentric pattern of LV and myocyte remodeling and resulting in preservation of LV function and contractility. Furthermore, we show for the first time, that the inhibition of hypertrophy by estrogen is dependent on estrogen-mediated regulation of calcineurin protein abundance through an ER-dependent pathway that increases calcineurin ubiquitination and degradation. These data represent a novel and previously unrecognized mechanism by which estrogen and its receptors regulate pathological cardiomyocyte growth.
|
Acknowledgments |
|---|
We thank Dr Ronglih Liao and her laboratory for generous assistance in developing the techniques of adult cardiac myocyte dispersion and culture.
Sources of Funding
This work was supported by the NIH grants R01-HL078003 (to R.D.P.) and R01-HL61298 (to R.H.K.).
Disclosures
None.
|
Footnotes |
|---|
*These authors contributed equally to this work.
Original received February 27, 2008; resubmission received October 31, 2008; accepted November 26, 2008.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. American Heart Association. Heart Disease and Stroke Statistics: 2005 Statistical Supplement. Dallas, Tex: American Heart Association; 2005.
2. Patten RD, Udelson JE, Konstam MA. LV dysfunction and heart failure following myocardial infarction. In: Sharpe N, ed. Heart Failure Management. London: Martin Duntz Ltd; 2000: 183–198.
3. Molkentin JD, Dorn GW II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63: 391–426.[CrossRef][Medline] [Order article via Infotrieve]
4. Patten RD. Cellular, molecular, and structural changes during cardiac remodeling. In: Hosenpud J, Greenberg B, eds. Congestive Heart Failure. 3rd ed. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2007: 128–146.
5. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215–228.[CrossRef][Medline] [Order article via Infotrieve]
6. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol (Lond). 2002; 541: 1–8.
7. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000; 87: 731–738.
8. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest. 2003; 112: 302–307.[CrossRef][Medline] [Order article via Infotrieve]
9. Hayward CS, Kelly RP, Collins P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res. 2000; 46: 28–49.
10. Patten R, Pourati I, Aronovitz M, Alsheikh-Ali A, Eder S, Force T, Mendelsohn M, Karas R. 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail. 2008; 14: 245–253.[CrossRef][Medline] [Order article via Infotrieve]
11. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation. 2001; 104: 1419–1423.
12. van Eickels M, Patten RD, Aronovitz MJ, Alsheikh-Ali A, Gostyla K, Celestin F, Grohe C, Mendelsohn ME, Karas RH. 17-beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol. 2003; 41: 2084–2092.
13. Wilkins BJ, Dai Y-S, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004; 94: 110–118.
14. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD. Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice. Proc Natl Acad Sci U S A. 2002; 99: 4586–4591.
15. Patten RD, Aronovitz MJ, Einstein M, Lambert M, Pandian NG, Mendelsohn ME, Konstam MA. Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond). 2003; 104: 109–118.[Medline] [Order article via Infotrieve]
16. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005; 289: H501–H512.
17. Georgakopoulos D, Mitzner WA, Chen C-H, Byrne BJ, Millar HD, Hare JM, Kass DA. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol Heart Circ Physiol. 1998; 274: H1416–H1422.
18. Chen X, Shevtsov SP, Hsich E, Cui L, Haq S, Aronovitz M, Kerkela R, Molkentin JD, Liao R, Salomon RN, Patten R, Force T. The {beta}-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol. 2006; 26: 4462–4473.
19. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH. 17{beta}-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res. 2004; 95: 692–699.
20. Jordan M, Wurm F. Transfection of adherent and suspended cells by calcium phosphate. Methods. 2004; 33: 136–143.[CrossRef][Medline] [Order article via Infotrieve]
21. Jain M, Brenner DA, Cui L, Lim CC, Wang B, Pimentel DR, Koh S, Sawyer DB, Leopold JA, Handy DE, Loscalzo J, Apstein CS, Liao R. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res. 2003; 93: e9–e16.[CrossRef][Medline] [Order article via Infotrieve]
22. Ni YG, Berenji K, Wang N, Oh M, Sachan N, Dey A, Cheng J, Lu G, Morris DJ, Castrillon DH, Gerard RD, Rothermel BA, Hill JA. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation. 2006; 114: 1159–1168.
23. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest. 2004; 114: 1058–1071.[CrossRef][Medline] [Order article via Infotrieve]
24. Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardiomyocyte hypertrophy in vitro: antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem. 2005; 280: 26339–26348.
25. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res. 2000; 87: e61–e68.[Medline] [Order article via Infotrieve]
26. Rothermel B, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem. 2000; 275: 8719–8725.
27. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001; 98: 3328–3333.
28. Sanna B, Brandt EB, Kaiser RA, Pfluger P, Witt SA, Kimball TR, van Rooij E, De Windt LJ, Rothenberg ME, Tschop MH, Benoit SC, Molkentin JD. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A. 2006; 103: 7327–7332.
This article has been cited by other articles:
 |
|
 |
|
  J. D. Gardner, D. B. Murray, T. G. Voloshenyuk, G. L. Brower, J. M. Bradley, and J. S. Janicki Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts Am J Physiol Heart Circ Physiol, February 1, 2010; 298(2): H497 - H504. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||